Vonoprazan/amoxicillin/clarithromycin explained
| Type: | combo |
| Component1: | Vonoprazan |
| Class1: | Potassium-competitive acid blocker |
| Component2: | Amoxicillin |
| Class2: | Beta-lactam antibiotic |
| Component3: | Clarithromycin |
| Class3: | Macrolide antibiotic |
| Tradename: | Vonosap, Voquezna Triple Pak |
| Dailymedid: | Voquezna |
| Atc Prefix: | A02 |
| Atc Suffix: | BD14 |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Legal Status: | Rx-only |
| Kegg: | D10775 |
Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.[2] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.
It was approved for medical use in Japan in 2016,[3] and in the United States in May 2022.[4] [5] [6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7] [8]
Further reading
- Kajihara Y, Shimoyama T, Mizuki I . Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication . Scandinavian Journal of Gastroenterology . 52 . 2 . 238–241 . February 2017 . 27806639 . 10.1080/00365521.2016.1250157 . 25801431 .
- Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, Sugimoto A, Takahashi K, Mukai K, Nakamatsu D, Matsubara T, Hayashi S, Yamamoto M, Nakajima S, Fukui K, Inada M . 6 . A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study . Digestion . 101 . 5 . 608–614 . 9 July 2019 . 31288235 . 10.1159/000501608 . vanc . 195871882 .
- Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N . 6 . Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility . Journal of Gastroenterology . 55 . 11 . 1054–1061 . November 2020 . 32930864 . 10.1007/s00535-020-01723-6 . 221674785 .
External links
- Web site: Vonoprazan . U.S. National Library of Medicine . Drug Information Portal .
- Web site: Amoxicillin . U.S. National Library of Medicine . Drug Information Portal .
- Web site: Clarithromycin . U.S. National Library of Medicine . Drug Information Portal .
Notes and References
- Web site: Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit . DailyMed . U.S. National Library of Medicine . 21 June 2022 . 3 July 2022 . 3 July 2022 . https://web.archive.org/web/20220703054730/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86 . live .
- Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S . Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis . Advances in Therapy . 38 . 7 . 3937–3947 . July 2021 . 34091865 . 8280045 . 10.1007/s12325-021-01784-w .
- Web site: Vonosap pack 400, Vonosap pack 800 and Vonopion pack (triple-drug blister packs containing Takecab tablet) Now Available for Helicobacter pylori[*] Eradication in Japan ]. Takeda . 7 June 2016 . 9 May 2022 . 10 May 2022 . https://web.archive.org/web/20220510031615/https://www.takeda.com/newsroom/newsreleases/2016/vonosap-pack-400-vonosap-pack-800-and-vonopion-pack-triple-drug-blister-packs-containing-takecab-tablet-now-available-for-helicobacter-pylori-eradication-in-japan/ . live .
- Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults . Phathom Pharmaceuticals . GlobeNewswire . 3 May 2022 . 9 May 2022 . 10 May 2022 . https://web.archive.org/web/20220510034341/https://www.globenewswire.com/en/news-release/2022/05/03/2435147/0/en/Phathom-Pharmaceuticals-Announces-FDA-Approval-of-VOQUEZNA-TRIPLE-PAK-vonoprazan-amoxicillin-clarithromycin-and-VOQUEZNA-DUAL-PAK-vonoprazan-amoxicillin-for-the-Treatment-of-H-pylo.html . live .
- Web site: FDA NDA approval . U.S. Food and Drug Administration (FDA) . 12 May 2022 . 12 May 2022 . https://web.archive.org/web/20220512000404/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215152Orig1s000,%20215153Orig1s000ltr.pdf . live .
- Web site: Voquezna Triple Pak (amoxicillin, clarithromycin, and vonoprazan) FDA Approval History. Drugs.com.
- Web site: Advancing Health Through Innovation: New Drug Therapy Approvals 2022 . U.S. Food and Drug Administration (FDA) . 10 January 2023 . 22 January 2023.
- New Drug Therapy Approvals 2022 . U.S. Food and Drug Administration (FDA) . January 2024 . PDF . 14 January 2024 . https://web.archive.org/web/20240114065648/https://www.fda.gov/media/164429/download . 14 January 2024 . live .
